Journal
JOURNAL OF LIPOSOME RESEARCH
Volume 31, Issue 1, Pages 30-44Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08982104.2020.1730400
Keywords
Osteoarthritis; chondroitin sulfate; nanovesicles; opioids; sublingual delivery; tapentadol; analgesics
Ask authors/readers for more resources
Recent treatment approaches of osteoarthritis face challenges due to various factors. This study aimed to develop targeted nanovesicles for effective management of OA by utilizing tapentadol HCl and chondroitin sulfate. The nanovesicles showed improved pharmacokinetics and sustained drug release, leading to enhanced analgesic activity in a disease-induced rat model.
Recent treatment approaches of osteoarthritis (OA) face a number of obstacles due to the progressive multitude of pain generators, nociceptive mechanisms, first pass mechanism, less efficacy and compromised safety. The present study was aimed to bring a novel approach for the effective management of OA, by developing sublingual targeted nanovesicles (NVs) bearing tapentadol HCl (TAP), surface modified with chondroitin sulfate (CS). Optimized nontargeted nanovesicle formulation (MB-NV) was developed by an ultrasound method, characterized as spherical in shape, nanometric in size (around 150 nm) with narrow size distribution (polydispersity index <0.5), and good entrapment efficiency (around 50%). MB-NV conjugated with CS which was confirmed by IR and H-1 NMR spectroscopy. C-MB-NV showed improved pharmacokinetics parameters i.e. increased t(1/2) (9.7 h), AUC (159.725 mu g/mL*h), and MRT (14.99 h) of TAP than nontargeted formulation and plain drug soln. C-MB-NV in in vitro release studies proved sustained drug release pattern for more than 24 h following Higuchi model kinetics with Fickian diffusion (n <= 0.5).Targeted nanovesicles exhibited an improved bioavailability and enhanced analgesic activity in a disease-induced Wistar rat model which indicated the superior targeting potential of C-MB-NV exploiting CD44 receptors as mediators, overexpressed at the affected joints in the OA model. It could be a propitious approach to accustomed therapies for methodical and efficient management in advanced OA therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available